Month: September 2026

AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system

SARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Food and Drug Administration (FDA) on September 25, 2026.

AI Highlights is designed to support physicians in the review of small bowel capsule endoscopy studies collected from adult and pediatric patients (over two years of age) in whom the study was performed due to suspected small bowel bleeding, specifically to reduce the time taken to review capsule endoscopy images. It does so through recognizing and marking images containing suspected abnormal lesions, which are highlighted and prioritized for physician review. The feature integrates with CapsoView®, CapsoVision’s video processing and review software, and supports workflows connected to the Company’s CapsoCloud® platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule. AI-processed studies can then support physician review within connected CapsoView or CapsoCloud workflows, depending on workflow configuration.

“FDA clearance of AI Highlights represents an important milestone in the continued evolution of the CapsoVision platform and our commitment to bringing integrated, AI-assisted technologies to physicians in the United States,” said Johnny Wang, President and Chief Executive Officer of CapsoVision. “Following the international launch of AI Highlights earlier this year, including in the European Union under the Medical Device Regulation, we are pleased to reach this important regulatory milestone in the United States. We believe AI-assisted review tools may help support physician efficiency and may help improve reading performance as capsule endoscopy adoption continues to expand.”

Integrated within the CapsoVision ecosystem, AI Highlights works across the connected CapsoCloud workflow to support capsule endoscopy review without the need for a separate AI platform. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management.

The AI Highlights reading tool that was reviewed and cleared by the FDA represents a part of comprehensive updates to the CapsoView and CapsoCloud software. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace gastroenterologists’ diagnostic interpretation or, where applicable, histopathological sampling. Please refer to the product’s Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video review. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected,” “anticipate(s),” “intend(s),” “plan(s),” “believe(s),” “potential,” “will,” “should,” “could,” “would,” “may,” “continue,” “remain,” “target(ed)”, “expand”, or “improve” and other words of similar meaning. Examples of these forward-looking statements include, but are not limited to, statements concerning possible or assumed future results of operations and financial position, including the Company’s expectations regarding the Company’s product and clinical development efforts, the timing and receipt of regulatory submissions and approvals, the Company’s plans, strategies and timing for its pipeline development the Company’s expectations regarding the potential benefits of AI-assisted review tools to support physician efficiency and reading performance, the Company’s expectations regarding continued expansion of capsule endoscopy adoption, and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions (including competition in the capsule endoscopy market), the Company’s financial condition and the availability of cash and financing, and the success of the Company’s product and clinical development efforts, These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s most recent Form 10-K and Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.

Investor Relations Contact

Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com

Media Contact

Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231

FREMONT, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Interlink Electronics, Inc. (Nasdaq: LINK), a leading provider of sensor and printed electronics solutions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 2:15 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/zbmgpRay9W7. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.   

About Interlink Electronics, Inc.
Interlink Electronics is a leading provider of sensors and printed electronic solutions, boasting 40 years of success in delivering mission-critical technologies across diverse markets. Our customers, including global blue-chip companies, trust our products and solutions, which span various markets, including medical, industrial, automotive, wearables, IoT, and other specialty markets. Our expertise in materials science, manufacturing, embedded electronics, firmware, and software enables us to create custom solutions tailored to our customers’ unique needs.

We serve our international customer base from our corporate headquarters and proprietary gas sensor production and product development facility in Fremont, California (Silicon Valley area); our advanced printed-electronics manufacturing center in Shenzhen, China; and our multiple facilities in Irvine, Scotland, and our smart textile and wearables product development footprint located in the Evolution Advanced Manufacturing Park in Rotherham, England.

For more information, please visit www.InterlinkElectronics.com.

Investor Relations Contact:
Interlink Electronics, Inc.
Steven N. Bronson, CEO
LINK@IESensors.com
805-623-4184

What You Should Know: 

• Bath & Body Works is launching Essentials, a new body care franchise made for sensitive skin, available in stores and online in the U.S. and Canada on Sept. 28 and more international markets next year.
• Every product is hypoallergenic, made for sensitive skin and dermatologist approved.*
• Essentials includes two new formulas, Skin Replenishing Body Wash and Ultra Hydrating Body Lotion, along with Eau de Parfum.
• Essentials features three soft and cozy fragrances — Vanilla Silk, Cashmere Amber and Suede Blossoms — designed to deliver a comforting self-care routine.

COLUMBUS, Ohio, Sept. 28, 2026 (GLOBE NEWSWIRE) — Bath & Body Works is launching Essentials, a new body care franchise that pairs hypoallergenic formulas made for sensitive skin with soft, close-to-skin fragrance. The collection introduces two new formulas, Skin Replenishing Body Wash and Ultra Hydrating Body Lotion, along with Eau de Parfum developed to a hypoallergenic standard.

Essentials launches in stores and online in the U.S. and Canada on Sept. 28, with select products also available on Amazon. The new line includes three new scents developed to a hypoallergenic standard: Vanilla Silk, with notes of vanilla, praline and sandalwood; Cashmere Amber, with notes of amber, mandarin and musk; and Suede Blossoms, with notes of jasmine, bergamot and tonka. Each fragrance is available across all three forms, allowing consumers to wash, moisturize and finish with Eau de Parfum.

Every Essentials product is dermatologist-approved, * made for sensitive skin and hypoallergenic. The pH-balanced Skin Replenishing Body Wash is made with glycerin and formulated to condition and nourish with every wash. The Ultra Hydrating Body Lotion is made with hyaluronic acid, shea butter and cocoa butter and provides 48 hours of continuous moisture and dry-skin relief. The Eau de Parfum offers a soft fragrance experience designed to stay close to the skin.

“Essentials was created to provide gentle care for consumers with sensitive skin,” said Kristie Lewis, executive vice president of merchandising at Bath & Body Works. “From the pH balanced Skin Replenishing Body Wash, made with glycerin, to the Ultra Hydrating Body Lotion, which delivers 48 hours of continuous moisture, every product was purposefully designed with sensitive skin in mind. Essentials is another example of our Consumer First Formula in action, delivering the gentle care consumers want from their daily routines, from the formulas themselves to packaging designed to feel calm, modern and elevated.”

Inspired by the calming feel of a spa, the Essentials packaging was designed to elevate everyday body care. The design takes cues from natural stone and marble, with subtle color variation to create a look and feel that is clean, soothing and elevated.

Bath & Body Works is partnering with board-certified dermatologist Dr. Michelle Henry to help consumers better understand the ingredients in Essentials and considerations for building a body care routine for sensitive skin.

“People with sensitive skin often look for products that support hydration while fitting easily into a daily routine,” said Dr. Michelle Henry, board-certified dermatologist. “The new franchise from Bath & Body Works includes familiar body care ingredients such as glycerin, hyaluronic acid, shea butter and cocoa butter, with formulas developed and tested for sensitive skin.”

For more information and to shop the Essentials collection, visit bathandbodyworks.com. Select products will also be available on Amazon.

ESSENTIALS PRODUCT DETAILS

Essentials features three soft, close-to-skin fragrances developed to a hypoallergenic standard: Vanilla Silk, with notes of vanilla, praline and sandalwood; Cashmere Amber, with notes of amber, mandarin and musk; and Suede Blossoms, with notes of jasmine, bergamot and tonka. Each fragrance is available in Skin Replenishing Body Wash ($18.95), Ultra Hydrating Body Lotion ($18.95) and Eau de Parfum ($39.95). The three formats are designed to be used as a routine: wash, moisturize and finish with Eau de Parfum.

ABOUT BATH & BODY WORKS

Bath & Body Works is a global leader in personal care and home fragrance, driven by the belief that everybody deserves to feel good.

The brand’s beloved scents are expertly crafted for performance and a luxury fragrance experience. Formulated with thoughtfully chosen ingredients, Bath & Body Works body care products are available in multiple forms, including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, sanitizer and more. The brand’s 3-wick candles are made with high-quality fragrance oils layered throughout a premium soy wax base for up to 45 hours of room-filling fragrance.

Consumers can shop Bath & Body Works in more than 1,900 stores in the U.S. and Canada, 550-plus international locations and select Ulta Beauty stores. Online, consumers can visit bathandbodyworks.com, Amazon and Ulta.com.

MEDIA CONTACT

communications@bbw.com

*Based on review of independent testing by board-certified dermatologist

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/06f44e0c-cb34-402a-8a2b-397fd77c005f 

https://www.globenewswire.com/NewsRoom/AttachmentNg/9074f32f-0db4-42f0-a4bc-c6fb4dd03ac8

Coop Pank AS (the Bank) announces that during the period 21.09.2026 – 27.09.2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
21.09.2026	9 264	2,36000000
22.09.2026	9 264	2,35000000
23.09.2026	9 264	2,32000000
24.09.2026	9 264	2,32500000
25.09.2026	9 264	2,30500000

Bank is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 8 April 2026, and under the conditions decided by the Supervisory Board and Management Board. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Coop Bank´s investor website.

Additional information:
Paavo Truu
CFO
Phone: 5160 231
E-mail: paavo.truu@cooppank.ee

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The bank has 239,100 clients who use everyday banking services. Coop Pank uses the synergy created between retail trade and banking and brings everyday banking solutions closer to people. The majority shareholder of the Bank is a domestic retail chain Coop Eesti, the sales network of which comprises over 330 stores.